Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansa Biopharma AB's book value per share for the quarter that ended in Jun. 2026 was kr-5.11.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Hansa Biopharma AB was 109.10% per year. The lowest was -34.90% per year. And the median was 9.90% per year.
During the past 13 years, the highest P/B Ratio of Hansa Biopharma AB was 52.69. The lowest was 3.33. And the median was 9.16.
Hansa Biopharma AB (CHIX:HNSAs) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Hansa Biopharma AB Book Value per Share Related Terms
Hansa Biopharma AB Book Value per Share Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:HNSAS vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (CHIX:HNSAS) has a Book Value per Share of kr-5.11 as of Jun. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Book Value per Share too high?
Hansa Biopharma AB's current Book Value per Share is kr-5.11. Overall, Hansa Biopharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Book Value per Share compare to VRTX and REGN?
Hansa Biopharma AB's Book Value per Share of kr-5.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Book Value per Share is kr-5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Book Value per Share of kr-5.11. The stock's GF Value™ is kr19.38, compared to a current price of kr25.64 — trading 32.3% above its estimated fair value. The current Book Value per Share is kr-5.11. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Book Value per Share is kr-5.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr25.64 is trading 32.3% above its estimated GF Value™ of kr19.38.
Key valuation signals for CHIX:HNSAS:
Book Value per Share: kr-5.11
GF Value™: kr19.38 vs. price of kr25.64 (32.3% above fair value)
No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for CHIX:HNSAS
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HNSAS has been successfully added to your 
